<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118257</url>
  </required_header>
  <id_info>
    <org_study_id>Pro8531</org_study_id>
    <nct_id>NCT04118257</nct_id>
  </id_info>
  <brief_title>Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors</brief_title>
  <official_title>Effects of Short-term Sugary Beverage Consumption on Type-2 Diabetes and Cardiovascular Disease Risk Factors: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansas State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansas State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to determine how the addition of sugar-sweetened beverages to the diet affects
      glucose control, cardiovascular disease risk factors, and pulmonary function in healthy,
      young adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a 3-arm randomized controlled trial, 36 participants consumed one of three beverages for
      three weeks: water (W), caffeine-free soda (S), or 100% fruit juice (FJ). Participants
      consumed two servings/day (~710mL) of their randomized beverage for three weeks, along with
      their habitual diets. At baseline and following the 3-week intervention, participants
      completed glucose control, cardiovascular disease risk factor, and pulmonary function
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Actual">November 14, 2018</completion_date>
  <primary_completion_date type="Actual">November 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucose iAUC</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Glucose obtained from blood sample in a fasted state and in response to a meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma lipids</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state and following consumption of a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic model assessment for insulin resistance</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Calculated from fasting glucose and insulin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Evaluated via automated sphygmomanometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Assessed using the maximum flow-volume loop</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin iAUC</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Glucose obtained from blood sample in a fasted state and in response to a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum fructosamine</measure>
    <time_frame>Week 0 and Week 3</time_frame>
    <description>Fructosamine obtained from blood sample</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Fruit Juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants consumed 2 bottles of water daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugary beverage: Fruit juice</intervention_name>
    <description>Participants consumed 100% fruit juice (~710mL) daily for three weeks, along with their habitual diets.</description>
    <arm_group_label>Fruit Juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugary beverage: Soda</intervention_name>
    <description>Participants consumed soda (~710mL) daily for three weeks, along with their habitual diets.</description>
    <arm_group_label>Soda</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control: Water</intervention_name>
    <description>Participants consumed water (~710mL) daily for three weeks, along with their habitual diets.</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Free from diagnosis of diabetes and pulmonary illness

          -  Have no intake of glucose or lipid lowering medication.

        Exclusion Criteria:

          -  Smoke

          -  Currently pregnant

          -  Have bronchitis

          -  Have more than 2 risk factors for cardiovascular disease, as defined by the American
             College of Sports Medicine (ACSM).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Rosenkranz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lafene Health Center</name>
      <address>
        <city>Manhattan</city>
        <state>Kansas</state>
        <zip>66502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kansas State University</investigator_affiliation>
    <investigator_full_name>Sara K Rosenkranz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Glucose control</keyword>
  <keyword>Cardiovascular disease risk factors</keyword>
  <keyword>Sugary beverages</keyword>
  <keyword>Pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

